News and price dashboard

Silence Therapeutics taken out by Merck KGaA

Silence Therapeutics is up 125.6%, and the reason is clean: Germany's Merck KGaA has agreed to buy the company in an all-cash deal, about $1.3 billion in equity value and $1.1 billion enterprise value. Holders get $20.00 per ADS, each ADS being three ordinary shares. That is a 130% premium to Friday's ADS close and an 82% premium to the 30-day VWAP of $10.99. Chairman and interim principal executive Iain Ross described it as the result of a competitive sale process delivering immediate and certain value. The structure is a UK scheme of arrangement under Part 26 of the Companies Act, needs shareholder approval, sanction by the High Court in England and Wales and regulatory clearances, and is expected to close in Q1 2027. The board approved unanimously and holders of roughly 14% of voting power have signed support agreements. Merck is buying the RNA platform that silences disease-causing protein production: lead asset divesiran in polycythemia vera, plus zerlasiran for elevated Lp(a). GuruFocus makes the point that from here the remaining return is tied to deal completion rather than clinical data.

Memory names bounce back, SanDisk and Micron

SanDisk is up 5.5% and Micron up 3.0%, a recovery from last week's memory selloff rather than anything new on fundamentals. GuruFocus notes Nasdaq 100 futures were up about 1.2% and S&P futures about 0.7% premarket, with falling oil easing inflation and rate worries, plus renewed attention on Nvidia reportedly asking Micron, SK Hynix and Samsung to use TSMC's 3nm process for base dies in custom HBM. SK Hynix gained 4.1%. Average analyst targets cited imply roughly 80% upside for Micron, 70% for SanDisk, 87% for SK Hynix. Context on how far SNDK fell: a separate GuruFocus piece describes a 17.9% single-day drop on a hotter-than-expected CPI print that pushed the VIX up nearly 30% to a four-month high, against a 857.8% first-half gain. SNDK trades at 19.03x trailing earnings versus a five-year median of 23.74x, GF Score 45, insiders sold $131.6 million over twelve months with no buying. The competitive overhang is China's ChangXin Memory, which fell 7.77% in Shanghai despite guiding to nine-month 2026 revenue of 265-270 billion yuan against 32.08 billion a year earlier and net profit of 131-132.5 billion. Western Digital, which reports fiscal Q1 late Thursday, led the S&P 500 up 6.1% to 352.21 per IBD. One TradingView post flagged a systematic long bracket order on SNDK at 1371.12 off an RSI cross above 30, stop 982.07, target 2927.36 — that's a retail chart setup, not news.

Datadog upgraded at Bernstein on AI token demand

Datadog is up 5.4%, driven by Bernstein's Peter Weed upgrading to Outperform from Market Perform with the target lifted to $350 from $237, and FY26/FY27 EPS estimates moved to $2.82 and $4.00. The notable thing is that Bernstein is reversing its own downgrade from last quarter, which had cited roughly $100 million of ARR cut from Datadog's largest "Born in AI" customer and weakness in the traditional base that makes up about 85% of revenue. Bernstein had expected net new ARR growth to slow to 20-30% in 2027 from 80-90% this year. That slowdown hasn't appeared: alternative data shows enterprise token consumption at the largest AI labs grew at least 50% quarter over quarter, possibly faster at smaller AI-native customers, with consumer agent launches Muse and Dots cited. Jefferies went the other way, trimming its target to $280 from $300. Schaeffer's notes the move snaps a five-day losing streak after the October 12 record high of $300.68, with the stock up 93.5% year to date, 42 of 46 covering brokers at buy or better, and a 10-day put/call ratio of 1.11 in the 91st percentile. GuruFocus flags the counterweight: GF Value $206.84 against a price around $260, so roughly 26% overvalued, trailing P/E of 531x versus a five-year median near 420x, GF Score 83 with growth at 10/10 but profitability 4/10, and insiders selling $905.8 million over twelve months with no buying. Q3 results land November 4. A TradingView write-up covers the same tension, arguing stock-based compensation and dilution matter as much as free cash flow growth here.

Arista, Accenture and TeraWulf valuation screens

Arista is up 3.4% to $182.95, though still down 13.2% on the week and 8.2% on the month, with GuruFocus putting it 7.5% above GF Value of $170.16 on a 57.7x trailing P/E against a 42.7x five-year median, a near-perfect GF Score of 99, and insiders having sold $1.50 billion over twelve months with no buying. Accenture is up 3.2% to $236.93 and screens the opposite way, 32.5% below GF Value of $351.20, with a 17.5x trailing P/E versus a 27.2x median and GF Score 87, though insiders sold $19.1 million and bought nothing. TeraWulf is up 3.3% to $12.06 but GuruFocus calls it 102% above GF Value of $5.97, GF Score 39, growth 0/10, trailing P/E of 180x against a 21.2x median, and net insider selling of $35.6 million over the year. Separately and headline-only, Accenture is reported to be eyeing a $1.5 billion exit in a key market as its AI strategy shifts.

Headline-only movers worth a glance

Several names moved on things I only have the headline for. NuScale is down 2.4% after Barclays downgraded it to Underweight and cut the target on execution risks, with a separate piece asking why the stock was down 6% intraday. Apple is down 0.2%, with Loop Capital downgrading to Hold and cutting its target to $330 from $370, the stated reason being that supply chain checks suggest Apple won't recover 13 million iPhone shipments cut from 2026 plans; separately Apple has set a product event for October 28 and committed up to $100 million for US titanium. AST SpaceMobile is up 3.0% on a European satellite spectrum collaboration. Nebius is up 2.9% alongside a broader neocloud rebound and a Truist $355 call. Revolution Medicines is up 2.4% having started a Phase 3 lung cancer trial, with Truist raising its target to $241. UiPath is up 2.1% despite CEO Daniel Dines selling 2.5 million shares for $33.07 million and Hedgeye naming it a top short. SpaceX is up 1.3% ahead of Q3 earnings, with heavy flow around Musk's pledge to gift SpaceX stock to children via Trump Accounts and Kalshi pricing a Tesla-SpaceX merger before February 2027 at 67%, up from about 30% earlier this month. Netflix is down 1.0% into tonight's after-close report, consensus EPS $0.82, amid back-to-back senior departures including film chief Dan Lin. Vicor is essentially flat at -0.4% after a Q3 earnings beat that reportedly sent shares up 5%.

Oil backdrop behind the tape

One item tagged to SLN is actually an OilPrice opinion piece by James Durso arguing a US ground invasion of Iran would be a strategic catastrophe, pointing to Iran's size, terrain and IRGC asymmetric preparations, and saying an invasion could push oil toward $200 a barrel. It has nothing to do with Silence Therapeutics, but the surrounding price board is relevant to the day: WTI around 100.5 and Brent around 111, up on tanker attacks in the Persian Gulf, Asian LNG past $30, and Canadian inflation at 3.1% with fuel oil up 58%. Falling oil in the US session was cited as part of why tech bounced.

Silence Therapeutics taken out by Merck KGaA

Silence Therapeutics is up 125.6% after agreeing to an all-cash takeover by Germany's Merck KGaA at $20.00 per American depositary share, each ADS representing three ordinary shares. That values the equity at roughly $1.3 billion and the enterprise at about $1.1 billion, and works out to a 130% premium to Friday's close and an 82% premium to the 30-day volume-weighted average of $10.99. Chairman and interim principal executive Iain Ross described it as the result of a competitive sale process delivering immediate and certain value. Merck is buying Silence's RNA platform, which silences production of disease-causing proteins; lead programme divesiran targets polycythemia vera and zerlasiran targets elevated lipoprotein(a). The structure is a UK scheme of arrangement, the board approved unanimously, and holders of about 14% of voting power have signed support agreements. Closing is guided for the first quarter of 2027, subject to shareholder approval, sanction by the High Court in England and Wales, and regulatory clearances. GuruFocus makes the point that the remaining upside is now tied to the deal closing rather than to clinical results. There is also an 8-K on file covering the material agreement.

OpenWorld falls on Blocksight merger news

OpenWorld is down 18.4% despite announcing a definitive merger agreement to acquire Blocksight Holdings, which builds AI agents that automate real-world asset tokenization — deal structuring, asset data verification, investor onboarding, daily reporting and servicing, with human sign-off at key decision points. The acquisition was first flagged on October 1 and the agents are to be folded into OpenWorld Enterprise. CEO Matt Shaw said programmes of that size cannot be verified and reported on by hand. Blocksight co-founders Patrick Kim and Peter Hong are expected to join on closing. Since the October 1 announcement OpenWorld signed two non-binding term sheets: one on October 7 with BeyondAI for an IP-backed transaction of up to $130 million, tokens representing rights to payments backed by patents and software rights, and one on October 15 with Meridian for a tokenized financing programme of up to $1 billion funding a distributed AI computing network run on solar and residential battery storage, initial deployment of 10,000 homes, with Meridian holding purchase rights to Tesla Powerwall systems and first installations due in Q4 2026 and a first commercial site in Q1 2027. Both term sheets are non-binding and the merger is still subject to customary closing conditions. None of the articles explains the share price drop. An 8-K covering the agreement and an unregistered equity sale is also on the list.

Memory names rebound after last week's selloff

SanDisk is up 5.7% and Micron up 3.0%, part of a broad memory bounce after a rough week. GuruFocus reported Micron up about 5% and SanDisk about 4% intraday, with SK Hynix adding 4.1%; Nasdaq 100 futures had been up nearly 1.2% and oil prices fell, easing inflation and rate pressure. The piece also notes renewed attention on Nvidia reportedly asking Micron, SK Hynix and Samsung to use TSMC's 3nm process for base dies in custom HBM, and cites average analyst targets implying roughly 80% upside for Micron, 70% for SanDisk and 87% for SK Hynix. The bear side is unchanged: scrutiny of AI infrastructure spending returns, and China's ChangXin Memory is pushing into DRAM — CXMT fell 7.77% in Shanghai even while guiding nine-month 2026 revenue to 265-270 billion yuan against 32.08 billion a year earlier and net profit of 131-132.5 billion yuan, reversing a prior-year loss. Separately, a GuruFocus piece covering last week's 17.9% SanDisk drop blamed a tech selloff on a hotter-than-expected CPI print, with the VIX up nearly 30% to a four-month high; it lists SanDisk's trailing P/E at 19.03x versus a five-year median of 23.74x, a GF Score of 45, $131.6 million of insider selling over twelve months with no buying, and a first-half gain of 857.8%. ETF flow data for October 15 shows net buying of $28.3 million in SNDK across 41 buyers and 16 sellers, led by DUHP at $37.5 million. There's also a headline-only Nasdaq "Bull of the Day: Sandisk" piece.

Datadog up on Bernstein upgrade

Datadog is up 5.3% after Bernstein SocGen's Peter Weed upgraded it to Outperform from Market Perform and lifted the target to $350 from $237. Bernstein had downgraded last quarter over a roughly $100 million ARR contract downsizing at Datadog's largest "Born in AI" customer, believed to be OpenAI, plus late-year softness in the traditional customer base that makes up about 85% of revenue, and had modelled net new ARR growth slowing to 20-30% in 2027 from 80-90% this year. That slowdown hasn't appeared: the firm's alternative data now shows enterprise token consumption at the biggest AI labs up at least 50% quarter over quarter, possibly faster at smaller Born in AI customers, helped by consumer AI agent launches Muse and Dots. Context matters here — the stock had fallen about 14% over the prior week from its October 12 record of $300.68, and today snaps a five-day losing streak. Jefferies trimmed its target to $280 from $300, while Mizuho had earlier raised to $330. Of 46 brokerages, 42 rate it buy or better against three holds and one strong sell. Schaeffer's notes a 10-day put/call ratio of 1.11, in the 91st percentile of its annual range, and a Volatility Scorecard of 84. GuruFocus flags the valuation side: GF Value of $206.84 against a price around $263.85, trailing P/E of 538x versus a five-year median of 419x, GF Score 83, and $905.8 million of insider selling over twelve months with no purchases. Q3 results are due November 4.

SpaceX headlines dominated by Musk share pledge and merger talk

SPCX is up 1.3% on a heavy but headline-only news flow. Musk posted that he will give one of his SpaceX shares to every kid in America next year, with one summary putting the implied total at roughly $10.7 billion across about 73 million children at $146.03 a share, and another headline saying the gift would be distributed via Trump Accounts. Separately, Tesla-SpaceX merger speculation picked up: one item cites Kalshi pricing a 67% chance of a merger before February 2027, up from around 30% earlier in the month, after a Tesla SEC filing revealed SpaceX board ties and change-of-control provisions, and Barclays analysts are said to anticipate an announcement before the December meeting. RBC reiterated its rating on a spectrum purchase. Tesla's redesigned Roadster, using SpaceX technology, and a Starlink Ukraine service controversy also feature. Earnings are coming and are framed as a test of Musk's AI spending ambitions.

Neoclouds and AI infrastructure bounce

Nebius is up 3.0%, part of the same rebound — one wire headline has CoreWeave up 6%, Nebius up 7% and IREN up 5.7% premarket, and another groups CoreWeave, Applied Digital, Nebius and IREN recovering after the AI selloff. Truist has a $355 call on Nebius which one headline frames as facing a cash-funding test, a director sold 7,260 shares, and November puts had surged 48% with shares at $165.47. Nvidia-backed Nscale's IPO is reported to be meeting valuation pushback. All headline-only.

Accenture and other mid-single-digit movers

Accenture is up 3.2% on two threads: a reported $1.5 billion sale of its Greater China unit, framed in the headlines around AI concerns, and an Accenture Federal partnership with Google to launch an AI agent deployment programme. Arista is up 3.3% with only a Form 4 filing and a DCF piece behind it, nothing with real content. WULF is up 3.3% on a technical post only. AST SpaceMobile is up 2.9%, with several outlets tying it to a European satellite spectrum collaboration and broadband push. TSMC is up 2.0% alongside headlines on new 3nm production at Kumamoto, Samsung's move for Nvidia chips, and JPMorgan ending a bearish Intel call held since 2022. Revolution Medicines is up 2.4% after Truist raised its target to $241, and Exelixis has a Citizens target raise to $65 on ESMO data.

Netflix into earnings

Netflix is down 1.0% ahead of its third-quarter report, with headlines centred on whether tone and guidance matter more than the beat, questions over user engagement, and the dismissal of film chief Dan Lin — the second senior content departure in a week. Headline-only throughout.

Apple quiet on price, noisy on flow

Apple is essentially flat at -0.1% but carries the longest headline list here, and it cuts both ways. A second October event is set for the 28th in LA, expected to feature new MacBook Pro models, an M6 chip and reportedly Apple's first touch-screen MacBook, with another item pointing to a November 6 launch including iMac. On demand, KeyBanc reiterated Underweight with a $250 target after surveying 2,046 iPhone users, warning higher prices and longer upgrade cycles could sap iPhone 18 momentum, and Jefferies flagged deteriorating Pro and Pro Max demand with China lead times at zero and reported component order cuts of 10-15%. Against that, JPMorgan reiterated Overweight on demand trends and Melius kept Buy with a $370 target, calling the rally to $5 trillion one nobody liked. Much of the rest is routine ETF rebalancing detail. All headline-only.

The rest

Red Cat is down 1.2% with a tender offer for Steyr Motors in the headlines, Steyr up 20% premarket and Clear Street backing the deal. PayPal is down 0.5% after a Cleveland Research downgrade on weakening trends. Joby is down 1.3% after Morgan Stanley cut its target to $10. Vicor reports Q3 shortly. Beyond that the list is filings, DCF screens and ETF flow notes with no real movement attached.

What the numbers in brackets are measuring

A caution before anything else: the bracketed moves are Friday's October 16 close, a broad AI-infrastructure selloff day, while several of the full articles below are dated October 19 and describe pre-market bounces off those lows. So Nebius shows -12.2% here and simultaneously has three pieces titled "Why is Nebius stock rallying today?" Both are true, just on different clocks.

Vicor down 12.9%

Vicor was the largest faller, down 12.9% to $191.50. The GuruFocus piece covering it is a valuation screen rather than news: no operating event is given for the drop. Their model puts fair value at $72.20 against that $191.50 price, a 165% premium, with a GF Score of 81/100 that pairs a growth sub-rank of 9/10 against a valuation rank of 1/10. Trailing P/E is 61.5x versus a five-year median of 74.0x, forward P/E 31.3x. Insiders sold $424.1m of stock over the past twelve months with no purchases. The 52-week range is $57.00 to $382.65.

Nebius and the neocloud unwind

Nebius is the densest story in the list, down 12.2% to $165.47 on Friday with volume around 31-35m shares, roughly 1.7x its monthly average, its sixth decline in eight sessions and on top of a 10% loss earlier that week. That was a sector move, not a company one: CoreWeave fell 11.9% to $61.39 the same session and lost about a quarter of its market value over the week on debt concerns, IREN fell 11.2%, and Nebius is down roughly 21-32% over the prior two weeks depending on which window the piece uses. The trigger behind the sector reassessment is laid out in the Nscale article: the Nvidia-backed London data centre developer is facing pushback on its roughly $30bn US IPO target, with investors arguing $16-19bn is more realistic, citing the collapse of Australian AI data centre firm Firmus's IPO plan. Microsoft, both investor and client, has pulled out of a UK data centre deal with Nscale after power constraints delayed the site, and its flagship Norway facility is six months behind schedule. Nscale filed publicly on September 18 and raised $3.36bn pre-IPO last month led by Third Point, with Nvidia, Apollo and Citadel participating.

What pushed Nebius back up Monday

By Monday pre-open Nebius was up 3.6%. Investing.com attributes it to a Truist note published Sunday evening reiterating Buy on both Nebius and CoreWeave with a $355 target on NBIS, arguing the Firmus collapse is not a read-across for providers with contracted backlogs and that Nebius's projected 4.5x 2028 EV/Sales is justified by above-average revenue growth. Alongside that, Nebius announced a $10m programme for European AI developers offering compute grants and capital access, with NVIDIA and Accel. Director Arne Grimme bought 296 shares at $169.99 on October 16, taking him to 6,181 shares; note the context, there has been one insider buy against 33 insider sells in the past year, totalling $318.2m sold. Earnings are scheduled for October 22. Two more sceptical pieces are in the list: GuruFocus flags a P/S of 34.12 against a historical median of 7.0, GF Score 52/100, negative EPS of -$0.13 and an Altman Z of 2.33, while a TradingView author focuses on the roughly $8.55bn of debt funding the 600MW Rotterdam build and the gap between $1.36bn of revenue and a 3.1% net margin and 0.4% ROE. A separate chart piece marks $234-240 as resistance and the weekly 50 EMA as support. Treat the TradingView items as individual opinion, not reporting.

Rocket Lab, Neutron slips to 2027

Rocket Lab fell 8.0% to $50.84, its eighth straight down day after drops of 8% and 7%. The cause is specific and company-level: on October 14 Rocket Lab said the Neutron rocket's debut is pushed into 2027 after air pockets were found in the propellant-tank dome, requiring a redesign and further testing. The underlying business is still growing, with Q2 revenue around $234m, up 62% year on year, backlog of $2.36bn, and a net loss of roughly $49m. GuruFocus puts P/S at 38.78 against a historical median of 18.88 and GF Value at $39.19, scoring it 77/100 with growth 10/10 and profitability 3/10. Insiders sold $683.3m over twelve months with no purchases, nine sells in the last three months. Two TradingView pieces take opposite sides, one mapping a path toward $40 and two headline-only posts framing the drop as a discounted entry.

Xometry down 8.7%

Xometry fell 8.7% to $90.91, again with no operating news attached. GuruFocus has GF Value at $48.11, an 89% premium, GF Score 71/100, forward P/E 70.5x, and net insider selling of $15.9m over the year ($4.0m bought, $20.0m sold). There is also a Form 144 filed October 17, which the article body does not detail beyond the filing itself.

AST SpaceMobile, European spectrum consortium

ASTS closed down 8.5% on Friday, having touched a 52-week low of $39.87, then rose 3.5-3.9% Monday pre-open. The substance: Deutsche Telekom, Orange, Telefónica and Vodafone signed a Letter of Intent to explore a joint bid for Mobile Satellite Services spectrum, covering a European market of over 500m subscribers, with AST providing European-operated ground infrastructure linking its BlueBird satellites to operator core networks and keeping data handling inside European jurisdiction. AST cites demonstrated peak downloads of 98.9 Mbps, next-generation satellites targeting close to 200 Mbps, and tuning across roughly 1,150 MHz of partner low- and mid-band spectrum plus its S-band priority rights. Separately, Boost Mobile founder and MobileX CEO Peter Adderton said publicly he bought near $40 and argued carriers may look to acquire AST or fold it into a consortium as a hedge against SpaceX. The 52-week high is $133.86 and the stated consensus rating is Hold.

Aurora and the Form 4 items

Aurora Innovation is shown down 10.1%, and the only item behind it is a Form 4 for director David Wehner dated October 1. The article carries no share count, price or reasoning, so there is nothing explaining the move. Same pattern across a batch of other names: Form 144s or Form 4s at Micron, Joby, Generac, Oracle, Apple, Broadcom, Credo, Kodiak, Take-Two, PayPal, NuScale and Mercury, all filing-notice headlines with no detail attached.

Iran headline, mis-tagged ticker

One item tagged to CAN (-8.2%) is actually a Walter Bloomberg post relaying Iran's foreign minister saying the Strait could open within six days if the US meets Iran's conditions, with talks resuming on the seventh day, sourced to a Telegram channel. It has nothing to do with the ticker it's filed under, and the replies to the post are openly sceptical of it. Relevant only as an oil-tape input.

Semis and large-cap tech, mostly headline-only

The semi and AI complex fell as a block and most of it is headline-level: Micron -5.6% with a headline tying it to the Nasdaq tech selloff, SanDisk -6.8%, Tower Semiconductor -6.8%, Credo -4.9%, Broadcom -4.5%, Oracle -4.6%, Arista -4.6%, Datadog -7.2% (where a Bernstein upgrade on AI demand strength is noted in a headline), TSMC -2.3%, Amphenol -2.6%. The one full-text item on the theme is a Japan wrap: the Nikkei 225 closed down 0.58% at 64,948.04, with Tokyo Electron -2.35% at ¥10,380 and SoftBank -1.31% at ¥4,879, Deutsche Bank attributing the move to investor anxiety over AI investment sustainability spilling over from Wall Street. Several GuruFocus DCF headlines sit alongside these, all flagging intrinsic values well below market, and they are headline-only valuation screens rather than news.

Smaller names with actual events

OpenWorld, down 7.3%, filed an 8-K and headlines say it signed a merger deal to acquire AI agent firm Blocksight, with a second 8-K covering officer and bylaw changes; no terms are visible from the headlines. Red Cat, down 3.7%, has headlines on a tender offer for Steyr Motors (Steyr shares reportedly up 20% pre-market) and a new long-endurance Trichon drone. Planet Labs fell 6.7%, with a director sale by Kristen Robinson of $565,560 and a Form 144. Beam Therapeutics fell 5.1% with CEO John Evans selling $1.19m. Silence Therapeutics, down 7.2%, filed an 8-K covering a material definitive agreement. William Blair initiated Revolution Medicines at Outperform; the stock closed down 6.0%. Citizens raised its Exelixis target to $65 on ESMO data.

SpaceX, Musk and the Tesla merger chatter

SPCX closed down 1.7% and carries the largest headline cluster in the list. Musk posted that he will give one SpaceX share to every child in America next year; a derived figure in one headline puts that at roughly 73m children at $146.03 a share, about $10.7bn. Other headlines cover Tesla's flying Roadster unveiling using SpaceX technology, Barclays analysts anticipating a Tesla-SpaceX merger announcement before the December meeting, Ukraine imposing speed limits on Starlink networks, and 24 ETFs adding to SPCX on October 15. All headline-level.

Apple and Netflix

Apple closed up 0.4%, the one green large cap, with a heavy but thin item load: JPMorgan reiterating Overweight on iPhone demand trends, a November 6 product launch including MacBook Pro and iMac, reported strong iPhone pre-orders with shipping slipping to January 2027, a new VP of global litigation, plus a long run of ETF flow notes. Netflix fell 2.9% ahead of its Q3 report this week, with one headline flagging questions on user engagement and another on a leadership reshuffle. Tesla, Meta, IBM and Spotify also report this week per the earnings-calendar posts, which is the backdrop several of the technical pieces above are positioning around.

The rest

Accenture was up 2.1%, with headlines on an AI agent deployment programme with Google Federal and a reported consideration of a $1.5bn sale of its Greater China unit. Everything else in the list, including Costco, Comcast, Paychex, Modine, Sezzle, SoundHound, Incyte, Avery Dennison and the SLV chart posts, moved less than a couple of percent or is chart commentary with nothing new behind it.

SMX collapses on huge volume

SMX closed down 47.5% at $1.89, on volume of about 10.8 million shares against a 20-day average near 256,000. The Yahoo page notes the stock's recent news flow was mostly company-authored promotional material about its molecular marking and Digital Material Passport platform for gold, silver, plastics and luxury goods, and explicitly says the drop was not tied to a fresh earnings update. No cause is given for the move itself. The day's range was $1.70 to $5.61, market cap is listed at about $2.1 million, and the stock is down roughly 99% year to date.

Vicor down on no stated news

Vicor fell 12.9% to $191.50. The GuruFocus piece covering it is a valuation note rather than an explanation: it puts GF Value at $72.20, calls the stock 165.2% overvalued, flags a GF Score of 81/100 with valuation ranked 1/10 and growth 9/10, and notes $424.1 million of insider selling over twelve months with no buying. Current P/E is 61.5x against a five-year median of 74.0x. The article gives no reason for Friday's decline.

Nebius hit in the neocloud selloff

Nebius dropped 12.2%, closing at $165.47 on roughly 31 million shares, about 1.7 times its one-month average and its sixth decline in eight sessions after a 10% loss earlier in the week. CoreWeave fell nearly 12% the same day, so this is sector-wide rather than company-specific. Five separate items cover the name. The funding question is the thread running through them: second-quarter operating cash inflow was $2.246 billion while purchases of property, equipment and intangibles took $5.657 billion, a $3.411 billion gap, with quarter-end cash of $8.042 billion plus $1.056 billion restricted. A TradingView piece ties the selloff to scrutiny of the planned 600 MW Rotterdam data center and roughly $8.55 billion of debt, with revenue of $1.36 billion, net margin of 3.1% and return on equity of 0.4%. Price-to-sales is 34.12 against a historical median near 7.0 (the TradingView author cites 38.1x). Dan Ives, per TipRanks on October 15, argued the neocloud selloff is a buying opportunity because higher rates squeeze financing rather than demand. Against that, insiders have sold $318.2 million over twelve months with no buys, though director Arne Grimme bought 296 shares at $169.99 on October 16, taking him to 6,181 shares. Earnings are set for October 22.

Aurora Innovation drops ahead of earnings

Aurora fell 10.1% to $4.855 on 35.7 million shares versus a 29.2 million average. The Yahoo page says coverage has centred on the driverless truck scaling plan and a fresh valuation debate, with regulatory progress noted but investors focused on whether the roadmap converts into revenue and lower cash burn. It says the drop came alongside articles questioning whether too much future growth is already priced in. Earnings are October 28. Oppenheimer maintained Outperform on October 8 and raised its target from $15 to $16.

Codexis and Xometry

Codexis fell 8.8% to $1.24, on volume of 980,000 against a 1.14 million average, so a sizeable move on below-average turnover and no news attached. Xometry fell 8.7% to $90.91. The one piece of hard news is a Form 144 filed October 17. The accompanying GuruFocus note is valuation commentary: GF Value $48.11 versus the $90.91 price, GF Score 71/100 with growth at 10/10 and valuation 1/10, forward P/E of 70.5x, and net insider selling of $15.9 million over twelve months ($4.0 million bought, $20.0 million sold).

Rocket Lab's Neutron delay

Rocket Lab fell 8.0% to $50.84, its eighth straight down day after drops of 8% and 7%. The cause is specific: the Neutron rocket's debut has slipped from Q4 2026 into 2027 after inspections found voids, tiny air pockets between carbon fibre layers, in the forward dome of the first-stage propellant tank. The defect appeared after a switch to automated fibre placement following an earlier qualification failure on a manually built tank. Peter Beck said "possible success isn't our standard." Engineers have replicated and fixed the process issue, an aft dome passed through the revised process, and replacement dome manufacturing plus first-stage hydrostatic and cryogenic testing are expected in Q1 2027. No new launch date was given. Analysts cut: KeyBanc's Michael Leshock went to $100 from $135, keeping Overweight, citing one fewer revenue-generating Neutron launch in 2027 and lower multiples across high-growth space names. Citizens' Trevor Walsh kept Market Outperform but cut from $130 to $90. On the other side, ARK bought 168,633 shares worth about $9.3 million on Thursday as the stock fell. Backlog was $2.36 billion at end-June, up 137% year on year, Q2 free cash flow was negative $110 million, and insiders have sold $683.3 million over twelve months with no purchases.

TeraWulf and the AI-adjacent names

TeraWulf fell 7.4% to $11.68, down 24.1% over the month and inside a 52-week range of $10.35 to $29.84. The GuruFocus note gives GF Value at $5.94, a GF Score of 38/100 with growth at 0/10, a forward P/E of 174.6x against a 21.2x historical median, and net insider selling of $35.6 million. Cantor Fitzgerald kept Overweight but cut its target to $30, per a headline-only item. Nearby in the same complex: Datadog down 7.2%, Tower Semiconductor down 6.8%, Micron down 5.6% with headlines attributing it to a Nasdaq tech selloff, Credo down 4.9%, Oracle down 4.6% with several technical pieces and one headline on AI debt, Arista down 4.6% and Broadcom down 4.5%, with one headline noting AI chip stocks flashing a signal not seen since 2015. Context from the quote pages: Nasdaq closed down 2.14%, S&P 500 down 1.09%, VIX up 21.45% to 19.99.

Other movers and headline-only items

UiPath fell 6.3%, with a GuruFocus headline calling it undervalued on GF Value. Revolution Medicines fell 6.0% as William Blair initiated at Outperform. Planet Labs fell 6.7%, alongside a Form 4 and a report that director Kristen Robinson sold $565,560 of stock. Xometry, Beam Therapeutics (down 5.1%, CEO John Evans sold $1.19 million), Joby, Generac, Accenture, Kodiak Gas and Credo all carry Form 4 or Form 144 filings. On the long list of Netflix headlines (down 2.9%): Peter Rice, formerly of Disney, was named Chief Content Officer amid a leadership shakeup and layoffs, earnings land next week, and BMO, Wedbush and Rosenblatt all appear with target or rating updates. TSMC fell 2.3% after record Q3 results, with Barclays raising to $670 and DA Davidson holding at $500, and a CEO comment that overseas fab expansion will dilute gross margin by 3 to 4 percentage points in the latter part of the five-year period. Apple rose 0.4% on the heaviest headline volume in the list, centred on the foldable iPhone Duo selling out within minutes of pre-orders opening, with delivery slipping toward January 2027, plus a UBS Neutral reiteration at $296 citing shorter Pro wait times and limited upside, and a UK CMA proposal on tap-to-pay access.

Iran and the Strait of Hormuz

A Walter Bloomberg post relays Iran's foreign minister saying that if the US complies with Iran's conditions, the strait can be open within six days with talks resuming on the seventh. That is the whole of it, sourced to a Telegram channel. Related headlines in the list reference tankers hit near Hormuz. Crude is quoted up 2.61% at $99.02 on the Yahoo pages.

SMX collapses on huge volume with no stated cause

SMX (Security Matters) fell 47.5%, closing at $1.89 against a $3.60 prior close, on 10.3 million shares versus a 256,000-share average. The day's range was $1.70 to $5.61, so it traded above and well below the open before settling at the low end. Market cap is now about $2.1 million, and the stock is down roughly 99% year to date and 88% over the past month. Nothing in the Yahoo page explains the drop. Yahoo's own summary note says the recent coverage is mostly company-authored material about its molecular-marking and traceability platform for gold, silver, plastics and textiles, and that the selloff points to pressure "beyond the company's promotional messaging." In other words, no stated reason. Balance sheet figures shown: $33.5 million total cash, trailing net loss to common of $189.9 million, levered free cash flow of -$30.9 million, 25 employees.

Nebius down 12% on AI funding fears

Nebius was the big liquid casualty, down 12.2%, and five separate items cover it. GuruFocus puts the close at $165.47, a loss of $22.94 on about 31 million shares, 1.7 times the one-month average, and the sixth decline in eight sessions after a 10% drop earlier in the week. The driver given is a sector-wide selloff in neocloud names, with CoreWeave off nearly 12% the same day. A second GuruFocus piece frames the funding math directly: second-quarter operating cash inflow was $2.246 billion against $5.657 billion of property, equipment and intangible purchases, a $3.411 billion gap, with quarter-end cash of $8.042 billion plus $1.056 billion restricted. That piece notes Dan Ives had argued on October 15 that the neocloud selloff was a buying opportunity because higher rates squeeze financing rather than demand. A TradingView note by KalaGhazi adds the specifics behind the worry: roughly $8.55 billion of debt financing capacity, a planned 600 MW Rotterdam data center, $1.36 billion of revenue mostly from Nebius AI Cloud, net margin of 3.1% and return on equity of 0.4%, against a 38.1x price-to-sales multiple. GuruFocus has P/S at 34.12 versus a historical median near 7.0, a GF Score of 52/100 with momentum 10/10 and valuation 2/10, and an Altman Z-score of 2.33. Insiders have sold $318.2 million over twelve months with no buys, against which director Arne Grimme's Form 4 purchase of 296 shares at $169.99 (taking him to 6,181 shares) is the lone offsetting item, reported separately twice. Earnings are scheduled for October 22.

Vicor falls 12.9%

Vicor dropped 12.9% to $191.50, inside a 52-week range of $57.00 to $382.65. The GuruFocus piece gives no operating news behind the move; it is a valuation note. GF Value is $72.20, which it calls 165.2% overvaluation, with a GF Score of 81/100 that breaks down as growth 9/10, momentum 9/10, financial strength and profitability 8/10 each, and valuation 1/10. Trailing P/E is 61.5x against a five-year median of 74.0x, forward P/E 31.3x. Insiders sold $424.1 million over the past twelve months with no purchases, and of seven gurus holding, two added and six trimmed.

Aurora Innovation off 10% ahead of earnings

Aurora fell 10.1% to $4.855 on 35.7 million shares against a 29.2 million average, a move of about 1.5 times its own 20-day ATR. The Yahoo page offers no single cause and points to the general mix of driverless truck scaling plans against cash burn and an unclear path to profitability, citing a new five-year US waiver for self-driving trucks and a management target of 30,000 trucks and $5 billion revenue by 2030. Q2 showed $2 million revenue against a $270 million loss, trailing free cash flow of -$414 million, and $1.22 billion cash. Earnings are due October 28. Oppenheimer maintained Outperform on October 8 and raised its target to $16 from $15.

Rocket Lab's eighth straight decline on the Neutron delay

Rocket Lab fell 8.0% to $50.84, the eighth consecutive down day after drops of 8% and 7%, and six items cover the same event. The first Neutron launch has slipped from Q4 2026 into 2027 after inspections found voids, tiny air pockets between carbon fibre layers, in the forward dome of the first-stage propellant tank. CEO Peter Beck said "possible success isn't our standard." The defect surfaced after the company moved to automated fibre placement following an earlier qualification failure on a manually built tank; engineers have reproduced the defect and changed the process, and an aft dome passed through the revised process. Replacement dome manufacturing and inspection are expected to finish before Q1 2027, with first-stage assembly and hydrostatic and cryogenic testing during that quarter. No new launch date was given. Two brokers cut targets while keeping positive ratings: KeyBanc's Michael Leshock to $100 from $135, citing one fewer revenue-generating Neutron launch in 2027 plus lower multiples across high-growth space names, and Citizens' Trevor Walsh to $90 from $130, keeping Market Outperform. On the other side, ARK bought 168,633 shares worth about $9.3 million on Thursday; that article also notes Q2 free cash flow of -$110 million, a June-end backlog of $2.36 billion, up 137% year on year, and an agreement covering 20 Electron launches. GuruFocus has GF Value at $39.19, a GF Score of 77/100 with growth 10/10 and profitability 3/10, P/S of 38.78 against a median of 18.88, EPS of -$0.28, and $683.3 million of insider selling over twelve months with no buys. A TradingView post by trader315269 reads the pullback as a technical entry into a 61.8–78.6% Fibonacci zone; it is a retail chart view, not research.

Codexis down 8.8% on light volume

Codexis fell 8.8% to $1.24 on 980,000 shares, below its 1.14 million average, which is worth noting because the move was large relative to its own volatility but not volume-driven. The Yahoo page gives no cause. It is down 51% over six months and 53% over a year. Q2 revenue was $14.91 million with a $12.01 million loss, cash of $54.9 million, debt-to-equity 220%. Earnings November 5. Piper Sandler kept Overweight on August 17 but cut its target to $8 from $9.

Xometry down 8.7% alongside a Form 144

Xometry fell 8.7% to $90.91, with a Form 144 filed October 17 noted separately. The GuruFocus piece is valuation-only and gives no operational reason: GF Value $48.11 against the $90.91 price, forward P/E 70.5x versus a five-year median near 3.8x, GF Score 71/100 with growth 10/10, momentum 9/10, profitability 3/10 and valuation 1/10. Insiders bought $4.0 million and sold $20.0 million over twelve months, a net $15.9 million of selling. The 52-week range is $35.86 to $112.94.

Iran, the Strait and oil

Iran's foreign minister said via Telegram that if the US complies with Iran's conditions, the Strait can open within six days with talks resuming on the seventh. That is the whole of the statement. For context from the quote boards in the same material, WTI was around $99 and Brent near $110. The item is tagged to CAN, which was down 8.2%; nothing in the material connects the two.

AI infrastructure and semis under broad pressure

A cluster of names moved down together with the Nasdaq off 2.14% and the VIX up 21% to 19.99. TeraWulf fell 7.4%, with Cantor Fitzgerald keeping Overweight and cutting its target to $30 per the headline. Datadog fell 7.2%, Tower Semiconductor 6.8%, SanDisk 6.8%, Micron 5.6%, Astera Labs 5.4% with Stifel reiterating at a $460 target, Credo 4.9%, Oracle 4.6%, Arista 4.6% and Broadcom 4.5%. These are headline-only, so no detail beyond the names and directions, but they line up with the same AI-financing anxiety that the Nebius and Rocket Lab full-text pieces describe. One related headline states Anthropic secured a BB+ rating from KBRA ahead of a $35 billion chip financing deal, with banks assembling a further $60 billion. Another says Microsoft pulled out of a UK data centre deal with Nscale, per the Telegraph.

Netflix ahead of earnings

Netflix fell 2.9% and carries the heaviest headline count on the list. The substance across those headlines: Peter Rice, formerly of Disney, has been named Chief Content Officer in a leadership shake-up accompanied by layoffs, and earnings are due next week alongside Tesla and Meta. Three brokers appear in headlines with targets lowered or held: BMO Capital to $125, Wedbush to $90, and Rosenblatt holding $75 at Neutral. These are headline-only, so the reasoning behind each is not available here.

Smaller moves and routine filings

TSMC fell 2.3% despite record Q3 results per one headline, with Barclays raising to $670 and DA Davidson holding $500; a separate headline covers a planned $4 billion Taiwan-backed AI hub in Texas, and a TSMC CEO quote says overseas fab expansion will dilute gross margin by 3 to 4 percentage points in the latter part of the five-year period. Planet Labs fell 6.7% with director Kristen Robinson selling $565,560 of stock. UiPath fell 6.3%. Revolution Medicines fell 6.0% as William Blair initiated at Outperform. Beam Therapeutics fell 5.1% with CEO John Evans selling $1.19 million. SpaceX was down 1.7% amid a long run of Starlink and Tesla-merger headlines, including Barclays calling a Tesla-SpaceX merger feasible but uncertain on timing and approval. Apple was up 0.4%, with headlines on the iPhone Duo foldable selling out at pre-order and delivery slipping into November, UBS reiterating Neutral at $296 on softer iPhone wait-time data, and a UK CMA proposal on tap-to-pay access. The rest of the list is Form 4 and Form 144 filings and chart posts with no substance behind them.

SMX collapses 47.5%

SMX was down 47.5%, closing at $1.89 after a day's range of $1.70 to $5.61 on volume of 10.3 million shares against a 20-day average of about 256,000. The Yahoo Finance page gives no stated reason for the drop. What it does show is a market cap of just $2.06 million, a 52-week range running from $1.70 up to $5,496, down roughly 99% year to date, with $33.5M total cash and levered free cash flow of -$30.9M. The company's own recent messaging has been about its molecular-marking and traceability platform for gold, silver, plastics and textiles. Shares ticked up 5.3% after hours.

Vicor down 12.9%

Vicor fell 12.9% to $191.50, inside a 52-week range of $57.00 to $382.65. The GuruFocus note attaches no company news to the move; it is a valuation piece, putting GF Value at $72.20 (so 165% above fair value on their method), a GF Score of 81/100 with growth 9/10 but valuation 1/10, a trailing P/E of 61.5x against a five-year median of 74.0x, forward P/E 31.3x, and insider sales of $424.1M over twelve months with no buying.

Nebius hit hardest of the AI infrastructure names

Nebius was down 12.2%, closing at $165.47 on roughly 31 million shares, about 1.7 times its one-month average and its sixth decline in eight sessions after a 10% loss earlier in the week. GuruFocus ties it to broad weakness in the neocloud group, with CoreWeave off nearly 12% the same day. The funding question is the thread running through all four Nebius pieces: Q2 operating cash inflow of $2.246 billion against $5.657 billion of property, equipment and intangibles purchases, a $3.411 billion gap, with $8.042 billion cash plus $1.056 billion restricted at quarter end. The TradingView piece frames the same issue around roughly $8.55 billion of debt and the planned 600 MW Rotterdam data center, noting revenue of $1.36 billion, net margin 3.1%, return on equity 0.4%, and a price-to-sales of 38.1x (GuruFocus puts P/S at 34.12 versus a historical median near 7.0). Dan Ives, via TipRanks on October 15, argued the selloff was a buying opportunity on the grounds that higher rates squeeze financing rather than demand. Against that, insiders have sold $318.2M over twelve months with 33 sells to one buy; the one buy was director Arne Grimme picking up 296 shares on October 16 at $169.99, taking him to 6,181 shares. Earnings are scheduled for October 22.

Aurora Innovation off 10.1%

Aurora fell 10.1% to $4.855 on 35.7 million shares against a 29.2 million average. Yahoo's page flags a five-year US waiver that removed one deployment hurdle for driverless trucks, while pointing to continued cash burn, losses, and a valuation some analysts call stretched. Q2 FY26 revenue was $2M against a $270M loss, trailing cash $1.22B, levered free cash flow -$414M. The average one-year target shown is $12.13, and Oppenheimer on October 8 kept Outperform while raising its target from $15 to $16. Earnings October 28.

Codexis and Xometry

Codexis was down 8.8% to $1.24, with no news attached on the Yahoo page beyond the price data: 52-week range $0.96 to $2.98, Q2 FY26 revenue $14.91M and a $12.01M loss, cash $54.9M, debt/equity 220%. Earnings November 5. Xometry fell 8.7% to $90.91, with a Form 144 filed the same day. The GuruFocus piece on it is valuation only, no operating news: GF Value $48.11 against the $90.91 price, GF Score 71/100 with growth 10/10 and valuation 1/10, forward P/E 70.5x, and net insider selling of $15.9M over twelve months ($4.0M bought, $20.0M sold).

Rocket Lab's Neutron delay, eighth straight down day

Rocket Lab was down 8.0% to $50.84, its eighth consecutive decline after drops of 8% and 7% earlier in the week. The cause is specific: inspections found voids, tiny air pockets between carbon fibre layers, in the forward dome of Neutron's first-stage propellant tank, pushing the debut launch from Q4 2026 into 2027. Peter Beck said "possible success isn't our standard." The defect appeared after a switch to automated fibre placement following an earlier manual-tank qualification failure; engineers have replicated it and changed the process, and an aft dome came through the revised process better. Replacement dome manufacturing and inspection is expected to finish before Q1 2027, with first-stage assembly and hydrostatic and cryogenic testing in that quarter. No new launch date. KeyBanc's Michael Leshock cut his target to $100 from $135 keeping Overweight, modelling one fewer revenue-generating Neutron launch in 2027 and citing lower multiples across high-growth space names; Citizens' Trevor Walsh kept Market Outperform but cut to $90 from $130. ARK bought 168,633 shares, about $9.3 million, on Thursday. Backlog was $2.36 billion at end-June, up 137% year on year, with Q2 free cash flow of -$110 million. Insiders have sold $683.3M over twelve months with no purchases.

TeraWulf

TeraWulf fell 7.4% to $11.68, down 24.1% over the month and 15.7% over the year, in a 52-week range of $10.35 to $29.84. The GuruFocus piece supplies no event behind the drop, only metrics: GF Value $5.94 against the price, GF Score 38/100 with growth 0/10 and financial strength 2/10, forward P/E 174.6x, and net insider selling of $35.6M. Separately, Cantor Fitzgerald kept Overweight and lowered its target to $30, headline only.

The semis and AI-complex backdrop

The common driver behind several of these is visible in the index data on the pages themselves: Nasdaq closed down 2.14%, S&P 500 down 1.09%, VIX up 21.45% to 19.99, with the 10-year at 5.10%. Headline-only items in your list point the same way, including one from Investing.com that the SOX chip index posted its longest losing streak since 2008 as AI worries deepened, and an item noting Anthropic received a BB+ rating from KBRA ahead of a $35 billion chip financing, with banks assembling a further $60 billion. Among your chip and AI names, Micron was down 5.6%, Astera Labs 5.4%, Credo 4.9%, Oracle 4.6%, Arista 4.6%, Broadcom 4.5%, TSMC 2.3%, with Tower Semiconductor off 6.8%. Datadog fell 7.2%. All of these are headline-only, so I can't tell you more than that the moves happened alongside the sector selloff.

Netflix cluster ahead of earnings

Netflix was down 2.9% on a heavy run of headline-only items: Peter Rice, formerly of Disney, named chief content officer, alongside reports of layoffs and a leadership shakeup, with an October 26 handover mentioned. BMO cut its target to $125, Wedbush to $90, Rosenblatt held at $75 with a Neutral rating. Earnings land next week alongside Tesla, Meta, IBM and others.

Smaller decliners and quieter names

UiPath was down 6.3%, Revolution Medicines 6.0% with William Blair initiating at Outperform, Planet Labs 6.7% with director Kristen Robinson selling $565,560 of stock, Beam Therapeutics 5.1% with CEO John Evans selling $1.19M, NioCorp 4.1% on two 8-K filings covering results and a material agreement, Sezzle 3.6%, Modine 3.3%, Generac 2.9%, Mercury Systems 2.8%, Amphenol 2.6%. All headline-only. Apple was the main gainer at up 0.4%, with pre-orders for the foldable iPhone Duo selling out within minutes and delivery dates slipping into January 2027, while UBS kept Neutral at $296 citing iPhone Pro wait times of four days versus longer in prior cycles. Accenture up 2.1%, Aflac 1.6%, Costco 1.1%, Paychex 0.8%. SpaceX fell 1.7% amid a thick but entirely headline-level stream on Starlink in Ukraine, spectrum, and Tesla merger speculation, including Barclays calling a merger feasible with uncertain timing, and Evercore raising its target to $275. Nothing in the rest of the list carries enough behind it to need your attention today.